Skip to main content
SpringerLink
Log in

Pathogenesis of Estrogen-Receptor-Positive and -Negative Breast Cancer

  • Chapter
Endocrine Oncology

Part of the book series: Contemporary Endocrinology ((COE))

Abstract

Over the last 20 years, there have been major advances in the treatment and prevention of breast cancer (BC), including the development and widespread use of mammography to detect cancer at an early stage, and the use of adjuvant chemotherapy or hormonal therapy to treat these early cancers to improve survival. Most recently, it has been shown that intervening at an even earlier stage is possible. Thus, clinical trials have demonstrated that it is possible to reduce BC incidence by treating women at high risk of developing BC with antiestrogens. Although all of these advances have improved the outcome for women with BC or women at high risk, cancer remains the leading cause of death in women aged 40–79 yr, with BC being the most common cause of cancer-related death in this age group, and the second most common cause of cancer-related death in women overall (1). In addition, hormonal therapies using antiestrogens may be ineffective in women who develop estrogen-receptor (ER)-negative BC. To continue to make progress in the treatment and prevention of this disease, it will be important to elucidate the steps in the genesis of BC. Detailed knowledge of the molecular events that occur to transform normal human mammary epithelial cells into invasive cancer will provide the clues for future efforts to irradicate this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Landis S, Murray T, Bolden S, Wingo P. Cancer Statistics 1999. CA J 1999; 49: 8–31.

    CAS  Google Scholar 

  2. Henderson BE, Ross R, Bernstein L. Estrogens as a cause of human cancer: the Richard and Hindau Rosenthal Foundation Award Lecture. Cancer Res 1988; 48: 246–253.

    PubMed  CAS  Google Scholar 

  3. Osborne M. Breast anatomy and development. In: Harris J, Lippman M, Morrow M, Hellman S, eds. Diseases of the Breast. Lippincott-Raven, Philadelphia, 1996, pp. 1–14.

    Google Scholar 

  4. Walter P, Green S, Greene G, Krust A, Bornert J, Jeltsch J, et al. Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci USA 1985; 82: 7889–7893.

    Article  PubMed  CAS  Google Scholar 

  5. Greene G, Gilna P, Waterfield M, Baker A, Hort Y, Shine J. Sequence and expression of human estrogen receptor complementary DNA. Science 1986; 231: 1150–1154.

    Article  PubMed  CAS  Google Scholar 

  6. Fuqua S. Chapter title. In: Harris J, Lippman M, Morrow M, Hellman S, eds. Diseases of the Breast. Lippincott-Raven, Philadelphia, 1996, pp. 261–271.

    Google Scholar 

  7. Knight W, Livingston R, Gregory E, McGuire W. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 1977; 37: 4669–4671.

    PubMed  CAS  Google Scholar 

  8. Adami H, Graffman S, Lindgren A, Sallstrom J. Prognostic implication of estrogen receptor content in breast cancer. Breast Cancer Res Treat 1985; 5: 293–300.

    Article  PubMed  CAS  Google Scholar 

  9. Clark G, Osborne C, McGuire W. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 1984; 2: 1102–1109.

    PubMed  CAS  Google Scholar 

  10. Foekens J, Portengen H, Putten WV Peters H, Krijnen H, Alexieva-Figusch J, Klijn J. Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res 1989; 49: 5823–5828.

    PubMed  CAS  Google Scholar 

  11. Clark G. Prognostic and predictive factors. In: Harris J, Lippman M, Morrow M, Hellman S, eds. Diseases of the Breast. Lippincott-Raven, Philadelphia, 1996, pp. 461–485.

    Google Scholar 

  12. Clark G, McGuire W. Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 1988; 15: 20–25.

    PubMed  CAS  Google Scholar 

  13. Kuiper G, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J-A. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93: 5925–5930.

    Article  PubMed  CAS  Google Scholar 

  14. Mosselman S, Polman J, Dijkema R. ERß: identification and characterization of a novel human estrogen receptor. FEBS 1996; 392: 49–53.

    Article  CAS  Google Scholar 

  15. Tremblay G, Tremblay A, Copeland N, Gilbert D, Jenkins N, Labrie F, Giguere V. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol Endocrinol 1997; 11: 353–365.

    Article  PubMed  CAS  Google Scholar 

  16. Ogawa S, Inoue S, Watanabe T, Hiroi H, Orimo A, Hosoi T, Ouchi Y, Muramatsu M. The complete primary structure of human estrogen receptor ß (hER(3) and its heterodimerization with ER a in vivo and in vitro. Biochem Biophys Res Commun 1998; 243: 122–126.

    Article  PubMed  CAS  Google Scholar 

  17. Kuiper G, Gustafsson J-A. The novel estrogen receptor-(3 subtype: potential role in the cell-and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett 1997; 410: 87–90.

    Article  PubMed  CAS  Google Scholar 

  18. Dotzlaw H, Leygue E, Watson P, Murphy L. Expression of estrogen receptor-beta in human breast tumors. J Clin Endocrinol Metab 1996; 82: 2371–2374.

    Article  Google Scholar 

  19. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjold M, Gustafsson J. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endorcrinol Metab 1997; 82: 4258–4265.

    Article  CAS  Google Scholar 

  20. Lu B, Leygue E, Dotzlaw H, Murphy L, Murphy L, Watson P. Estrogen receptor-P mRna variants in human and murine tissues. Mol Cell Endocrinol 1998; 138: 199–203.

    Article  PubMed  CAS  Google Scholar 

  21. Leygue E, Dotzlaw H, Watson P, Murphy L. Altered estrogen receptor a and (3 messenger RNA expression during human breast tumorigenesis. Cancer Res 1998; 58: 3197–3201.

    PubMed  CAS  Google Scholar 

  22. Brandenberger A, Tee M, Jaffe R. Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. J Clin Endocrinol Metab 1998; 83: 1025–1028.

    Article  PubMed  CAS  Google Scholar 

  23. Watanabe T, Inoue S, Ogawa S, Ishii Y, Hiroi H, Ikeda K, Orimo A, Muramatsu M. Agnostic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: functional difference between estrogen receptors alpha and beta. Biochem Biophys Res Commun 1997; 236: 140–145.

    Article  PubMed  CAS  Google Scholar 

  24. Paech K, Webb P, Kuiper G, Nilsson S, Gustafsson J-A, Kushner P, Scanlan T. Differential ligand activation of estrogen receptors ERa and ER(3 at AP1 sites. Science 1997; 277: 1508–1510.

    Article  PubMed  CAS  Google Scholar 

  25. Shibata H, Spencer T, Onate S, Jenster G, Tsai S, Tsai M, O’Malley B. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Prog Horm Res 1997; 52: 141–164.

    PubMed  CAS  Google Scholar 

  26. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985; 312: 146–151.

    Article  PubMed  CAS  Google Scholar 

  27. Dupont WD, Parl FF, Hartmann WH, Brinton LA, Winfield AC, Worrel JA, Schuyler AP, Plummer WD. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 1993; 71: 1258–1265.

    Article  PubMed  CAS  Google Scholar 

  28. Morrow M, Schnitt S, Harris F. In situ carcinomas. In: Harris J, Lippman M, Morrow M, Hellman S, eds. Diseases of the Breast. Lippincott-Raven, Philadelphia, 1996, pp. 355–376.

    Google Scholar 

  29. Rosenberg CL, Larson PS, Romo JD, De Las Morenas A, Faller DV. Microsatellite alterations indicating monoclonality in atypical hyperplasias associated with breast cancer. Human Pathol 1997; 28: 214–219.

    Article  CAS  Google Scholar 

  30. O’Connell P, Pekkel V, Fuqua S, Osborne CK, Allred DC. Molecular genetic studies of early breast cancer evolution. Breast Cancer Res Treat 1994; 32: 5–12.

    Article  PubMed  Google Scholar 

  31. O’Connell P, Pekkel V, Fuqua SAW, Osborne CK, Allred DC. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 1998; 90: 697–703.

    Article  PubMed  Google Scholar 

  32. Lakhani SR, Slack DN, Hamoudi RA, Collins N, Stratton MR, Sloane JP. Detection of allelic imbalance indicates that a proportion of mammary hyperplasia of usual type are clonal neoplastic proliferations. Lab Invest 1996; 74: 129–135.

    PubMed  CAS  Google Scholar 

  33. Ricketts D, Turnbull L, Tyall G, Bakhshi R, Rawson NSB, Gazet JC, Nolan C, Coombes RC. Estrogen and progesterone receptors in the normal female breast. Cancer Res 1991; 51: 1817–1822.

    PubMed  CAS  Google Scholar 

  34. Peterson OW, Hoyer PE, van Deurs B. Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue. J Natl Cancer Inst 1986; 77: 343–349.

    Google Scholar 

  35. Allegra JC, Lippman ME, Green L, Barlock A, Simon R, Thompson EB, Hugg KK, Griffin W. Estrogen receptor values in patients with benign breast disease. Cancer 1979; 44: 228–231.

    Article  PubMed  CAS  Google Scholar 

  36. Battersby S, Robertson BJ, Anderson TJ, King RJB, McPherson K. Influence of menstrual cycle, parity, and oral contraceptive use on steroid hormone receptors in normal breast. Br J Cancer 1992; 65: 601–607.

    Article  PubMed  CAS  Google Scholar 

  37. Markopoulos C, Berder U, Wilson P, Gazet JC, Coombes RC. Oestrogen receptor content of normal breast cells and breast carcinoma throughout the menstrual cycle. Br Med J 1988; 296: 1149–1351.

    Article  Google Scholar 

  38. Giri DD, Dundas AC, Nottingham JF, Underwood JCE. Oestrogen receptors in benign epithelial lesions and intraduct carcinomas of the breast: an immunohistological study. Histopathology 1989; 15: 575–584.

    Article  PubMed  CAS  Google Scholar 

  39. Karayiannakis AJ, Bastounis EA, Chatzigianni EB, Makri GG, Alexiou D, Karamanakos P. Immunohistochemical detection of oestrogen receptors in ductal carcinoma in situ of the breast. Eur J Surg Oncol 1996; 22: 578–582.

    Article  PubMed  CAS  Google Scholar 

  40. Zafrani B, Leroyer A, Fourquet A, Laurent M, Torphilme D, Validire P, Sastre-Garau A. Mammographically detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53, and c-erbB-2 proteins, and proliferative activity. Semin Diagn Pathol 1994; 11: 208–214.

    PubMed  CAS  Google Scholar 

  41. Burr M, Zimarowski M, Schnitt S, Baker S, Lew R. Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer 1992; 69: 1174–1181.

    Article  Google Scholar 

  42. Khan S, Rogers M, Khurana K, Meguid M, Numann P. Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 1998; 90: 37–42.

    Article  PubMed  CAS  Google Scholar 

  43. Khan S, Rogers M, Obando J, Tamsen A. Estrogen receptor expression of benign breast epithelium and its association with breast cancer. Cancer Res 1994; 54: 993–997.

    PubMed  CAS  Google Scholar 

  44. Dickson R, Lippman M. Oncogenes and suppressor genes. In: Harris J, Lippman M, Morrow M, Hellman S, eds. Diseases of the Breast. Lippincott-Raven, Philadelphia, 1996, pp. 221–234.

    Google Scholar 

  45. Allred D, Harvey J, Berardo M, Clark G. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155–168.

    PubMed  CAS  Google Scholar 

  46. Mansour O, Zekri A, Harvey J, Teramoto Y, el-Ahmady O. Tissue and serum c-erbB-2 and tissue EGFR in breast carcinoma: three years follow-up. Anticancer Res 1997; 17: 3101–3106.

    PubMed  CAS  Google Scholar 

  47. Johannsson O, Idvall I, Anderson C, Borg A, Barkardottir R, Egilsson V, Olsson H. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997; 33: 362–371.

    Article  PubMed  CAS  Google Scholar 

  48. Consortium BCL. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet 1997; 349: 1505–1510.

    Article  Google Scholar 

  49. Eiseinger F, Jacquemier J, Charpin C, Stoppa-Lyonnet D, Paillerets BB.-d, Peyrat J, et al. Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res 1998; 58: 1588–92.

    Google Scholar 

  50. Sourvinos G, Spandidos D. Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors. Biochem Biophys Res Commun 1998; 245: 75–80.

    Article  PubMed  CAS  Google Scholar 

  51. Rhei E, Bogomolniy F, Federici M, Maresco D, Offit K, Robson M, Saigo P, Boyd J. Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers. Cancer Res 1998; 58: 3193–3196.

    PubMed  CAS  Google Scholar 

  52. Henderson B, Bernstein L. Endogenous and exogenous hormonal factrors. In: Harris J, Lippman M, Morrow M, Hellman S, eds. Diseases of the Breast. Lippincott-Raven, Philadelphia, 1996, pp. 185–200.

    Google Scholar 

  53. Henderson B, Ross R, Judd H, Krailo M, Pike M. Do regular ovulatory cycles increase breast cancer risk? Cancer 1985; 56: 1206–1208.

    Article  PubMed  CAS  Google Scholar 

  54. Henderson B, Gerkins V, Rosario I, Casagrande J, Pike M. Elevated serum levels of estrogen and prolactin in daughters of patients with breast cancer. N Engl J Med 1975; 293: 790–795.

    Article  PubMed  CAS  Google Scholar 

  55. Trichopoulus D, Brown J, Garas J, Papaioannou A, MacMahon B. Elevated urine estrogen and pregnanediol levels in daughters of breast cancer patients. J Natl Cancer Inst 1981; 67: 603–606.

    Google Scholar 

  56. MacMahon B, Trichopoulos D, Brown J, Andersen A, Aoki K, Cole P, et al. Age at menarche, probability of ovulation and breast cancer risk. Int J Cancer 1982; 29: 13–16.

    Article  PubMed  CAS  Google Scholar 

  57. Trichopoulos D, MacMahon B, Cole P. Menopause and breast cancer risk. J Natl Cancer Inst 1972; 48: 605–613.

    PubMed  CAS  Google Scholar 

  58. Henderson B, Ross R, Pike M, Casagrande J. Endogenous hormones as a major factor in human cancer. Cancer Res 1982; 42: 3232–3239.

    PubMed  CAS  Google Scholar 

  59. DeWaard F, Cornelis J, Aoki K, Yoshida M. Breast cancer incidence according to weight and height in two cities of the Netherlands and in Aichi prefecture, Japan. Cancer 1977; 40: 1269–1275.

    Article  CAS  Google Scholar 

  60. Hunter D, Willet W. Nutrition and breast cancer. Cancer Causes Control 1996; 7: 56–68.

    Article  PubMed  CAS  Google Scholar 

  61. Steinberg K, Thacker S, Smith S, Stroup D, Zack M, Flanders W, Berkelman R. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991; 265: 1985–1990.

    Article  PubMed  CAS  Google Scholar 

  62. Sillero-Arenas M, Delgado-Rodriguez M, Rodigues-Canteras R, Bueno-Cavanillas A, Galvez-Vargas R. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol 1992; 79: 286–294.

    PubMed  CAS  Google Scholar 

  63. Collaborative Group on Hormonal Factors in Breast Cancer, I.C.E.U., Radcliffe Infirmary, Oxford, UK. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713–1727.

    Article  Google Scholar 

  64. Yuan J, Yu M, Ross R, Gao Y, Henderson B. Risk factors for breast cancer in Chinese women in Shanghai. Cancer Res 1988; 48: 1949–1953.

    PubMed  CAS  Google Scholar 

  65. Enger S, Ross R, Henderson B, Bernstein L. Breastfeeding history, pregnancy experience and risk of breast cancer. Br J Cancer 1997; 76: 118–123.

    Article  PubMed  CAS  Google Scholar 

  66. Newcomb P, Storer B, Longnecker M, Mittendorf R, Greenberg E, Clapp R, et al. Lactation and a reduced risk of premenopausal breast cancer. N Engl J Med 1994; 330: 81–87.

    Article  PubMed  CAS  Google Scholar 

  67. Bernstein L, Ross R, Lobo R, Hanisch R, Krailo M, Henderson B. The effects of moderate physical activity on mentrual cycle patterns in adolescence: implications for breast cancer prevention. Br J Cancer 1987; 55: 681–685.

    Article  PubMed  CAS  Google Scholar 

  68. Bernstein L, Henderson B, Hanisch R, Sullivan-Halley J, Ross R. Physical exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst 1994; 86: 1403–1408.

    Article  PubMed  CAS  Google Scholar 

  69. Parazzini F, Braga C, Vecchia CL, Negri E, Acerboni S, Franceschi S. Hysterectomy, oophorectomy in premenopause, and risk of breast cancer. Obstet Gynecol 1997; 90: 453–456.

    Article  PubMed  CAS  Google Scholar 

  70. Schairer C, Persson I, Falkeborn M, Naessen T, Troisi R, Brinton L. Breast cancer risk associated with gynecologic surgery and indications for such surgery. Int J Cancer 1997; 70: 150–154.

    Article  PubMed  CAS  Google Scholar 

  71. Kuukasjarvi T, Kononen J, Helin H, Holli IG, Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996; 14: 2584–2589.

    PubMed  CAS  Google Scholar 

  72. Holdaway I, Bowditch F, Bowditch J. Variation in receptor status between primary and metastatic breast cancer. Cancer 1983; 52: 479–485.

    Article  PubMed  CAS  Google Scholar 

  73. Osborne C. Heterogeneity in hormone receptor status in primary and metastatic breast cancer. Semin Oncol 1985; 12: 317–326.

    PubMed  CAS  Google Scholar 

  74. Hull D, Clark G, Osborne C, Chamness G, Knight W, McGuire W. Multiple estrogen receptor assays in human breast cancer. Cancer Res 1983; 43: 413–416.

    PubMed  Google Scholar 

  75. Encarnacion C, Ciocca D, McGuire W, Clark G, Fuqua S, Osborne C. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 1993; 26: 237–246.

    Article  PubMed  CAS  Google Scholar 

  76. Zhang Q, Borg A, Wolf D, Oesterreich S, Fuqua S. Estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res 1997; 57: 1244–1249.

    PubMed  CAS  Google Scholar 

  77. Zhang Q, Hilsenbeck S, Fuqua S, Borg A. Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. J Steroid Biochem Mol Biol 1996; 59: 251–260.

    Article  PubMed  CAS  Google Scholar 

  78. Murphy L, Leygue E, Dotzlaw H, Douglas D, Coutts A, Watson P. Oestrogen receptor variants and mutations in human breast cancer. Ann Med 1997; 29: 221–234.

    Article  PubMed  CAS  Google Scholar 

  79. McGuire W, Chamness G, Fuqua S. Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 1991; 5: 1571–1577.

    Article  PubMed  CAS  Google Scholar 

  80. Moore J, McKee D, Slentz-Kesler K, Moore L, Jones S, Home E, et al. Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 1998; 247: 75–78.

    Article  PubMed  CAS  Google Scholar 

  81. Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, Muramatsu M. Molecular cloning and characterization of human estrogen receptor bcx: a potential inhibitor of estrogen action in humans. Nucleic Acids Res 1998; 26: 3505–3512.

    Article  PubMed  CAS  Google Scholar 

  82. Vladusic E, Hornby A, Guerra-Vladusic F, Lupu R. Expression of estrogen receptor beta messenger RNA variant in breast cancer. Cancer Res 1998; 58: 210–214.

    PubMed  CAS  Google Scholar 

  83. Lu B, Leygue E, Dotzlaw H, Murphy L, Murphy L, Watson P. Estrogen receptor-beta mRNA variants in human and murine tissues. Mol Cell Endocrinol 1998; 138: 199–203.

    Article  PubMed  CAS  Google Scholar 

  84. Elledge R, Green S, Ciocca D, Pugh R, Allred D, Clark G, et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 1998; 4: 7–12.

    PubMed  CAS  Google Scholar 

  85. Allred D, Clark G, Molina R, Tandon A, Schnitt S, Gilchrist K, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992; 23: 974–979.

    Article  PubMed  CAS  Google Scholar 

  86. Carlomagno C, Perrone F, Gallo C, Laurentiis MD, Lauria R, Morabito A, et al. c-erb B2 over-expression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996; 14: 2702–2708.

    PubMed  CAS  Google Scholar 

  87. Schroeder W, Biesterfeld S, Zillessen S, Rath W. Epidermal growth factor receptor-immunohistochemical detection and clinical significance for treatment of primary breast cancer. Anticancer Res 1997; 17: 2799–2802.

    PubMed  CAS  Google Scholar 

  88. Zeillinger R, Kury F, Czerwenka K, Kubista E, Sliutz G, Knogler W, et al. HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene 1989; 4: 109–114.

    PubMed  CAS  Google Scholar 

  89. Adnane J, Gaudray P, Simon M, Simony-Lafontaine J, Jeanteur P, Theillet C. Proto-oncogene amplification and human breast tumor phenotype. Oncogene 1989; 4: 1389–1395.

    PubMed  CAS  Google Scholar 

  90. Harris A, Nicholson S, Sainsbury R, Wright C. Farndon J. Epidermal growth factor receptor and other oncogenes as prognostic markers. J Natl Cancer Inst Monogr 1992; 11: 181–187.

    PubMed  Google Scholar 

  91. Eppenberger U, Kueng W, Schlaeppi J, Roesel J, Benz C, Mueller H, et al. Markers of tumor angiogenesis and proteolysis independently define high-low-risk subsets of node-negative breast cancer patients. J Clin Oncol 1998; 16: 3129–3136.

    PubMed  CAS  Google Scholar 

  92. Yiangou C, Gomm J, Coope R, Law M, Luqmani Y, Shousha S, Coombes R, Johnston C. Fibroblast growth factor 2 in breast cancer: occurrence and prognostic significance. Br J Cancer 1997; 75: 28–33.

    Article  PubMed  CAS  Google Scholar 

  93. Miller D, El-Ashry D, Cheville A, Liu Y, McLeskey S, Kern F. Emergence of MCF7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression. Cell Growth Differ 1994; 5: 1263–1274.

    PubMed  CAS  Google Scholar 

  94. Liu Y, El-Ashry D, Chen D, Ding I, Kern F. MCF7 breast cancer cells overexpressing transfected cerbB2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res Treat 1995; 34: 97–117.

    Article  PubMed  CAS  Google Scholar 

  95. Benz C, Scott G, Sarup J, Johnson R, Tripathy D, Coronado E, Shepard H, Osborne C. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1993; 24: 85–95.

    Article  CAS  Google Scholar 

  96. El-Ashry D, Miller D, Kharbanda S, Lippman M, Kern F. Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis. Oncogene 1997; 15: 423–435.

    Article  PubMed  CAS  Google Scholar 

  97. Wise S, Smith L, Hendricks D, Sabichi A, Bober M, Brown P, Birrer M. Over-expression of the cJun oncoprotein in the human breast cancer cell line MCF-7 results in tamoxifen resistance and increased invasiveness. Proc Am Assoc Cancer Res 1997; 38: 173.

    Google Scholar 

  98. Fairchild C, Ivy S, Kao-Shan C, Whang-Peng J. Rosen N, Israel M, et al. Isolation of amplified and over-expressed DNA sequences from adriamycin-resistant human breast cancer cells. Cancer Res 1987; 47: 5141–5148.

    PubMed  CAS  Google Scholar 

  99. Vickers P, Dickson R, Shoemaker R, Cowan K. A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol Endocrinol 1988; 2: 886–892.

    Article  PubMed  CAS  Google Scholar 

  100. Reddel R, Alexander I, Koga M, Shine J, Sutherland R. Genetic instability and the development of steroid hormone insensitivity in cultured T 47D human breast cancer cells. Cancer Res 1988; 48: 4340–4347.

    PubMed  CAS  Google Scholar 

  101. Graham M, Smith J, Jewett P, Horwitz K. Heterogeneity of progesterone receptor content and remodeling by tamoxifen characterize subpopulations of cultured human breast cancer cells: analysis by quantitative dual parameter flow cytometry. Cancer Res 1992; 52: 593–602.

    PubMed  CAS  Google Scholar 

  102. Sartorius C, Groshong S, Miller L, Powell R, Tung L, Takimoto G, Horwitz K. New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP’. Cancer Res 1994; 54: 3868–3877.

    PubMed  CAS  Google Scholar 

  103. Graham M, Dalquist K, Horwitz K. Simultaneous measurement of progesterone receptors and DNA indices by flow cytometry: analysis of breast cancer cell mixtures and genetic instability of the T47D line. Cancer Res 1989; 49: 3943–3949.

    PubMed  CAS  Google Scholar 

  104. Horwitz K, Mockus M, Lessey B. Variant T47D human breast cancer cells with high progesterone-receptor levels despite estrogen and antiestrogen resistance. Cell 1982; 28: 633–642.

    Article  PubMed  CAS  Google Scholar 

  105. Murphy C, Pink J, Jordan V. Characterization of a receptor-negative hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions. Cancer Res 1990; 50: 7285–7292.

    PubMed  CAS  Google Scholar 

  106. Nasca P, Liu S, Baptiste M, Kwon C, Jacobson H, Metzger B. Alcohol consumption and breast cancer: estrogen receptor status and histology. Am J Epidemiol 1994; 140: 980–988.

    PubMed  CAS  Google Scholar 

  107. Reichman M, Judd J, Longcope C, Schatzkin A, Clevidence B, Nair P, Campbell W, Taylor P. Effects of alcohol consumption on plasma and urinary hormone concentrations in premenopausal women. J Natl Cancer Inst 1993; 85: 722–727.

    Article  PubMed  CAS  Google Scholar 

  108. Johnston SR, Saccani-Jotti G, Smith I, Salter J, Newby J, Coppen M, Ebbs S, Dowsett M. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 1995; 55: 3331–3338.

    PubMed  CAS  Google Scholar 

  109. Raemaekers J, Beex L, Koenders A, Pieters G, Smals A, Benraad T, Kloppenborg P. Concordance and discordance of estrogen and progesterone receptor content in sequential biopsies of patients with advanced breast cancer: relation to survival. Eur J Cancer Clin Oncol 1984; 20: 1011–1018.

    Article  PubMed  CAS  Google Scholar 

  110. Tilley W, Keightley D, Cant E. Inter-site variation of oestrogen receptors in human breast cancers. Br J Cancer 1978; 38: 544–546.

    Article  PubMed  CAS  Google Scholar 

  111. Davis B, Zava D, Locher G, Goldhirsch A, Hartmann W. Receptor heterogeneity of human breast cancer as measured by multiple intratumoral assays of estrogen and progesterone receptor. Eur J Cancer Clin Oncol 1984; 20: 375–382.

    Article  PubMed  CAS  Google Scholar 

  112. Allegra J, Barlock A, Huff K, Lippman M. Changes in multiple or sequential estrogen receptor determinations in breast cancer. Cancer 1980; 45: 792–794.

    Article  PubMed  CAS  Google Scholar 

  113. Welshons W, Jordan V. Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. Eur J Cancer Clin Oncol 1987; 23: 1935–1939.

    Article  PubMed  CAS  Google Scholar 

  114. Herman M, Katzenellenbogen B. Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to transhydroxytamoxifen. J Steroid Biochem Mol Biol 1996; 59: 121–134.

    Article  PubMed  CAS  Google Scholar 

  115. Katzenellenbogen B, Kendra K, Norman M, Berthois Y. Proliferation hormonal responsiveness and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 1987; 47: 4355–4360.

    PubMed  CAS  Google Scholar 

  116. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998; 90: 1371–1388.

    Article  PubMed  CAS  Google Scholar 

  117. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352: 98–101.

    PubMed  CAS  Google Scholar 

  118. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Roberson C, Rotmensz N, Boyle P. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998; 352: 93–97.

    PubMed  CAS  Google Scholar 

  119. Delmas P, Bjarnason H, Mitlak B, Ravoux A, Shah A, Huster W, Draper M, Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641–1647.

    Article  PubMed  CAS  Google Scholar 

  120. Gail M, Benichou J. Validation studies on a model for breast cancer risk. J Natl Cancer Inst 1994; 86: 573–575.

    Article  PubMed  CAS  Google Scholar 

  121. Cummings S, Norton L, Eckert S, Grady D, Cauley J, Knickerbocker R, et al. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women. Two-year findings from the Multiple Outcomes of Raloxifene Evaluation trial. Proc Am Soc Clin Oncol 1998; 17: 2a.

    Google Scholar 

Download references

Authors
  1. Powel Brown MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Suzanne Fuqua PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Craig Allred MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, University of Michigan Cancer Center, Ann Arbor, MI, USA

    Stephen P. Ethier PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Brown, P., Fuqua, S., Allred, C. (2000). Pathogenesis of Estrogen-Receptor-Positive and -Negative Breast Cancer. In: Ethier, S.P. (eds) Endocrine Oncology. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-223-4_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-223-4_4

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9700-7

  • Online ISBN: 978-1-59259-223-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation